+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years - 17Years
All Genders
ID05509777

Evaluating Mirikizumab Treatment in Children and Adolescents With Crohns Disease Across Multiple Centers

Led by Eli Lilly and Company · Updated on 2026-10-07

90

Participants Needed

81

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of mirikizumab in children and adolescents aged 2 to 17 years with moderately to severely active Crohns disease. The study aims to assess the drugs effectiveness, safety, tolerability, and how well it is absorbed in the body. This phase 3 clinical trial involves participants with confirmed Crohns disease or fistulizing Crohns disease who have shown an inadequate response or intolerance to at least one prior medication. Participants will receive mirikizumab intravenously or subcutaneously, with dosing based on their weight category. The study includes a 12-week induction period, followed by a maintenance phase lasting from week 12 to week 52. After the treatment periods, there is a safety follow-up period lasting up to 16 weeks. Overall, the study will last approximately 74 weeks and may involve up to 19 visits. Throughout the study, participants will undergo various assessments including clinical response evaluations using the Pediatric Crohns Disease Activity Index PCDAI and endoscopic scoring. Researchers will monitor changes in inflammatory markers such as C-reactive protein and fecal calprotectin, as well as pharmacokinetic measures of mirikizumab. Safety and tolerability will be tracked during the follow-up period, with all evaluations scheduled at multiple timepoints throughout the study.

CONDITIONS

Brief Title

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here